Literature DB >> 2368727

Multidisciplinary adverse drug reaction surveillance program.

T R Prosser1, P L Kamysz.   

Abstract

Initial experience with a multidisciplinary adverse drug reaction (ADR) surveillance program at a 350-bed community hospital center is described. The pharmacy and quality-review (QR) departments developed a program that was incrementally incorporated into the hospital's overall QR activity. After inservice training, nurses and QR personnel were asked to complete an "alert" card for every suspected ADR and send it to the pharmacy. In addition, medical records were reviewed retrospectively for disease classification codes related to drug toxicity and unspecified adverse effects. Laboratory and utilization-review personnel also conducted retrospective reviews. A pharmacist reviewed all ADR reports and categorized each according to the severity of the reaction and the probability that it was drug related. For each reaction classified as severe, the patient's chart underwent physician peer review for appropriateness of therapy, avoidability of the reaction, and adequate documentation; related patient-care issues were addressed by the medical staff as part of routine quality-review activities. When problems with prescribing were identified, the pharmacy and therapeutics committee intervened with the prescribers or recommended further medical staff review. Drugs repeatedly associated with ADRs became the focus of drug-use reviews. The number of ADR reports increased from 0 to 134 in the first 11 months of the program. A multidisciplinary approach to ADR reporting increased the number and quality of ADR reports.

Entities:  

Mesh:

Year:  1990        PMID: 2368727

Source DB:  PubMed          Journal:  Am J Hosp Pharm        ISSN: 0002-9289


  11 in total

1.  Academic detailing improves identification and reporting of adverse drug events.

Authors:  R G Schlienger; T F Lüscher; R A Schoenenberger; W E Haefeli
Journal:  Pharm World Sci       Date:  1999-06

2.  Computerized survelliance of adverse drug reactions in hospital: pilot study.

Authors:  T Azaz-Livshits; M Levy; B Sadan; M Shalit; G Geisslinger; K Brune
Journal:  Br J Clin Pharmacol       Date:  1998-03       Impact factor: 4.335

3.  Critical gaps in the world's largest electronic medical record: Ad Hoc nursing narratives and invisible adverse drug events.

Authors:  John F Hurdle; Charlene R Weir; Beverly Roth; Jennifer Hoffman; Jonathan R Nebeker
Journal:  AMIA Annu Symp Proc       Date:  2003

4.  Development of a combined system for identification and classification of adverse drug reactions: Alerts Based on ADR Causality and Severity (ABACUS).

Authors:  Yvonne Koh; Chun Wei Yap; Shu-Chuen Li
Journal:  J Am Med Inform Assoc       Date:  2010 Nov-Dec       Impact factor: 4.497

5.  Development of a computerized adverse drug event monitor.

Authors:  R S Evans; S L Pestotnik; D C Classen; S B Bass; R L Menlove; R M Gardner; J P Burke
Journal:  Proc Annu Symp Comput Appl Med Care       Date:  1991

6.  The profile of voluntary reported adverse drug reactions at a tertiary care hospital: a fifteen month prospective study.

Authors:  Amit Dang; P N Bhandare
Journal:  J Clin Diagn Res       Date:  2012-11

Review 7.  Strategies to improve adverse drug reaction reporting: a critical and systematic review.

Authors:  Cristian Gonzalez-Gonzalez; Elena Lopez-Gonzalez; Maria T Herdeiro; Adolfo Figueiras
Journal:  Drug Saf       Date:  2013-05       Impact factor: 5.606

8.  Cost evaluation of adverse drug reactions in hospitalized patients in Taiwan: A prospective, descriptive, observational study.

Authors:  Agnes L F Chan; Haw Yu Lee; Chi-Hou Ho; Thau-Ming Cham; Shun Jin Lin
Journal:  Curr Ther Res Clin Exp       Date:  2008-04

9.  The role of pharmacists in adverse drug reaction reporting.

Authors:  P I Roberts; D J Wolfson; T G Booth
Journal:  Drug Saf       Date:  1994-07       Impact factor: 5.606

10.  Adverse drug reaction monitoring in a secondary care hospital in South India.

Authors:  R Arulmani; S D Rajendran; B Suresh
Journal:  Br J Clin Pharmacol       Date:  2007-07-27       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.